CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $10M Series C, bringing the round total to $14M. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.

Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage small molecule company focused on isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, closed a $40M Series C financing. Participants include Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners.

TriVascular (Santa Rosa, CA) a commercial-stage medical device company focused on endovascular repair devices for the treatment of abdominal aortic aneurysms, closed a $60M Series C financing. Participants include Pinnacle Ventures, New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.

Curexo Technology (Korea) a commercial-stage medical device company focused on robotic surgical systems for joint replacement, closed a $13.2M Series C financing. Participants were not identified.

Molecular Detection (Wayne, PA) a commercial-stage molecular diagnostics company focused on MRSA detection, closed a $1.4M Series C financing, bringing the total round to $4.7M. Participants include MentorTech Ventures.

EarlySense (Israel) a development-stage medical device company focused on acute care patient supervision, closed a $13M Series C financing. Participants include Pitango Venture Capital, Etgar Challenge Fund, Proseed Ventures, Docor International Management, Noaber and Bridge Investment.

Coronado Biosciences (Seattle, WA) a clinical-stage biopharmaceutical oncology company focused on AML, NSCLC, leukemia, lymphoma, and prostate cancer. Participants were not identified.

Action Pharma (Denmark) a clinical-stage biopharmaceutical company focused on acute kidney injury in patients undergoing cardiac surgery and inflammation, closed a $6.3M Series C financing. Participants include Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital.

Healthline Networks (San Francisco, CA) a commercial-stage content provider of health information services, closed a $14M Series C financing. Participants include Investor Growth Capital, Peacock Equity Fund and Reed Elsevier Ventures.